BioCorRx Inc. (BICX)
Oxford Ledge is still expanding full research coverage of BICX. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
BioCorRx develops addiction treatment programs and an implantable naltrexone pellet through its subsidiaries.
SEC filings
- 10-Q Quarterly financial report (unaudited) 2026-05-15
- 8-K Entry into material agreement; 3.02; Financial statements and exhibits 2026-04-02
- 10-K Annual financial report with audited statements 2026-03-31
- 10-Q Quarterly financial report (unaudited) 2025-11-14
- 10-Q Quarterly financial report (unaudited) 2025-08-14
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for BICX. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open BICX in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.